| Autor: |
Dreteler, G. H., Wouters, W., Toorop, G. P., Jansen, J. A. P., Saxena, P. R. |
| Zdroj: |
Journal of Cardiovascular Pharmacology; March 1991, Vol. 17 Issue: 3 p488-493, 6p |
| Abstrakt: |
The systemic and regional hemodynamic effects of the centrally acting 5-Hydroxytryptamine1A(5-HT1A) receptor agonist flesinoxan (0.5 and 2.5 mg kg1. intraarterially, i.a.) were investigated in conscious freely moving spontaneously hypertensive rats (SHR) and compared with those of 8-hydroxy-2(di-N-propylamino)-tetralin (8-OH-DPAT) (0.1 and 0.5 mg kg 1, i.a.). In one group of animals, cardiac output (CO) was measured with a precalibrated electromagnetic flow probe around the ascending aorta. In another group, regional vascular conductances were measured using radioactive microspheres. Flesinoxan and 8-OH-DPAT dose dependently decreased blood pressure (BP) (22 ± 5 and 13 ± 4, respectively, at the highest dose) mainly resulting from an increase in total peripheral vascular conductance (TPC) (34 ± 12 and 16 ± 3, respectively) since there was no effect on CO. Both drugs reduced heart rate (HR) (17 ± 4 and 20 ± 4 for flesinoxan and 8-OH-DPAT, respectively, at the highest dose). Flesinoxan and B-OH-DPAT showed a qualitatively similar pattern with regard to their effects on vascular conductances, causing increases in vascular conductances in the heart and skeletal muscles in contrast to results in a saline-treated group. Vascular conductances in the lungs were markedly increased by both tlesinoxan and 8-OH-DPAT, which may indicate that the conductance in the arteriovenous shunt vessels was enhanced. These results demonstrate that tlesinoxan and 5-OH-DPAT elicit a qualitatively similar systemic and regional hemodynamic profile in conscious SHR. Furthermore, the increase in TPC appears to be due mainly to vasodilatation in the skeletal muscles. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
